No­var­tis scores sixth Cosen­tyx ap­proval from FDA, this time to treat hidradeni­tis sup­pu­ra­ti­va

No­var­tis on Tues­day nabbed an­oth­er in­di­ca­tion for its bi­o­log­ic Cosen­tyx (se­cuk­inum­ab), this time in the grow­ing field of treat­ments tar­get­ing the skin con­di­tion hidradeni­tis sup­pu­ra­ti­va in adults.

The ap­proval, the sixth in­di­ca­tion for Cosen­tyx, is based on pos­i­tive Phase III da­ta from the com­pa­ny’s SUN­SHINE and SUN­RISE tri­als. The re­sults showed that a high­er pro­por­tion of pa­tients giv­en a 300 mg dose of Cosen­tyx ei­ther every two or four weeks re­spond­ed com­pared to a place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER